drugset / Trial / NCT02272868

Fecal Microbial Transplant in Pediatric Crohn's Disease

NCT02272868

Phase 1/2 Terminated 7 enrolled Seattle Children's Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a double blind placebo control trial of fecal microbial transplantation for active Crohn's disease in patients 12 to 21 years of age.

Timeline

Start
2015-01
Primary completion
2016-10-01
Completion
2016-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Fecal Microbial Transplant Other / unclassified 90 ml Other
Background Omeprazole Other / unclassified 20 mg
Background Rifaximin Other / unclassified 400 mg Oral
Background polyethylene glycol Other / unclassified 17 g

Indications